Wu Mengfei, Gao Shanshan, Song Huadan, Zhang Zihan, Zheng Zhiyuan, Yan Zhiping, Wang Xiaolin, Wang Jianhua, Liu Lingxiao
Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Shanghai Institute of Medical Imaging, Shanghai, 200032, China.
J Interv Med. 2019 Jul 30;2(2):55-59. doi: 10.1016/j.jimed.2019.07.003. eCollection 2019 May.
To evaluate the safety and efficacy of percutaneous microwave ablation (MWA) combined with simultaneous transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) patients with microvascular invasion (MVI) or extrahepatic metastases (EHM).
Between August 2012 and April 2017, 101 patients with MVI/EHM of HCC underwent percutaneous MWA combined with simultaneous TACE at our center. The clinical data were collected and analyzed for survival and prognostic factors.
The mean follow-up time was 23.6 ± 14.7 months. One patient had grade 3 complications, and the median overall survival was 12.0 months (95% confidence interval 9.7-14.3). Multivariate analysis showed that Child-Pugh class, serum alpha-fetoprotein level, and Eastern Cooperative Oncology Group performance status were independent factors of survival.
Our results suggest that percutaneous MWA combined with simultaneous TACE is a safe and effective treatment for HCC with MVI/EHM.
评估经皮微波消融（MWA）联合同期经动脉化疗栓塞术（TACE）治疗伴有微血管侵犯（MVI）或肝外转移（EHM）的肝细胞癌（HCC）患者的安全性和有效性。
2012年8月至2017年4月期间，101例伴有MVI/EHM的HCC患者在本中心接受了经皮MWA联合同期TACE治疗。收集临床数据并分析生存情况及预后因素。
平均随访时间为23.6±14.7个月。1例患者出现3级并发症，中位总生存期为12.0个月（95%置信区间9.7 - 14.3）。多因素分析显示，Child-Pugh分级、血清甲胎蛋白水平和东部肿瘤协作组体能状态是生存的独立因素。
我们的结果表明，经皮MWA联合同期TACE是治疗伴有MVI/EHM的HCC的一种安全有效的方法。
